Fight Aging! Newsletter, November 4th 2019

In this study, we hypothesized that moderately and chronically reducing ACh could attenuate the deleterious effects of aging on NMJs and skeletal muscles. To test this hypothesis, we analyzed NMJs and muscle fibers from heterozygous transgenic mice with reduced expression of the vesicular ACh transporter (VAChT), VKDHet mice, which present with approximately 30% less synaptic ACh compared to control mice. Because ACh is constitutively decreased in VKDHet, we first analyzed developing NMJs and muscle fibers. We found no obvious morphological or molecular differences between NMJs and muscle fibers of VKDHet and control mice during development. In contrast, we found that moderately reducing ACh has various effects on adult NMJs and muscle fibers. VKDHet mice have significantly larger NMJs and muscle fibers compared to age-matched control mice. They also present with reduced expression of the pro-atrophy gene, Foxo1, and have more satellite cells in skeletal muscles. These molecular and cellular features may partially explain the increased size of NMJs and muscle fibers. Thus, moderately reducing ACh may be a therapeutic strategy to prevent the loss of skeletal muscle mass that occurs with advancing age. Low Dose Quercetin as a Geroprotector in Mice https://www.fightaging.org/archives/2019/10/low-dose-quercetin-as-a-geroprotector-in-mice/ Quercetin is used in combination with dasatinib as a senolytic treatment capable of selectively destroying senescent ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs

Related Links:

ConclusionsE-cigarette use should be assessed and monitored to understand the safety and potential efficacy of e-cigarettes as a harm reduction approach for HF patients.
Source: Heart and Lung: The Journal of Acute and Critical Care - Category: Respiratory Medicine Source Type: research
Condition:   Malignant Neoplasm Interventions:   Drug: Fentanyl Sublingual Spray;   Drug: Morphine;   Other: Physical Performance Testing;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   D011471;   D064129;   D035683;   D009360;   D014408 Intervention:   Diagnostic Test: Periodic ARV7 and miRNA evaluation Sponsor:   Azienda Ospedaliero-Universitaria Careggi Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Hepatitis B Interventions:   Biological: Recombinant Hepatitis B (Bio Farma) Vaccine;   Biological: Recombinant Hepatitis B (Bio Farma) Vaccine® Sponsor:   PT Bio Farma Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Locally Advanced Colon Cancer Intervention:   Combination Product: CAPECITABINE AND OXALIPLATIN Sponsor:   Universidad de León Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Patients With Metastatic Colorectal Cancer Interventions:   Drug: Fluoropyrimidine;   Drug: Bevacizumab Sponsor:   Centre Hospitalier Universitaire Dijon Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Breast Cancer Interventions:   Drug: Avelumab;   Drug: Aspirin;   Drug: Lansoprazole Sponsors:   The Christie NHS Foundation Trust;   University of Manchester Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Osteoarthritis, Knee Interventions:   Behavioral: Change in sleeping position;   Behavioral: No change in sleeping position Sponsor:   University of Bradford Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Latent Tuberculosis Intervention:   Other: TB Infection ECHO Sponsors:   Kent Hospital, Rhode Island;   National Institute of General Medical Sciences (NIGMS) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Nutrition;   Physical Activity Interventions:   Behavioral: Intervention Physical Activity;   Other: Usual Care Sponsors:   University of North Carolina, Chapel Hill;   University of Texas Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Academia | Alopecia | Alzheimer's | Antidoxidants | Biochemistry | Bioflavonoids | Biology | Biotechnology | Bone Cancers | Brain | Brain Cancers | Breast Cancer | Cancer | Cancer & Oncology | Cancer Vaccines | Cardiology | Cardiomyopathy | Cardiovascular | Chemotherapy | Chronic Obstructive Pulmonary | Clinical Trials | Colon Cancer | Colorectal Cancer | Conferences | Cytology | Databases & Libraries | Dementia | Diabetes | Diabetes Type 2 | Diets | Economic Slowdown | Economy | Education | Endocrinology | Environmental Health | Esophagus Cancer | Eyes | Fruit | Gastroschisis Repair | Genetics | Heart | Heart Attack | Heart Disease | Heart Failure | Hypertension | Infectious Diseases | Influenza | Influenza Vaccine | Insulin | Laboratory Medicine | Liver | Lung Cancer | Minerals | Mitochondria | Molecular Biology | Nanotechnology | Neurology | Neuroscience | Nicotine | Nutrition | Oral Cancer | Orthopaedics | Osteoarthritis | Osteoporosis | Osteosarcoma | Parkinson's Disease | Pensions | Pharmaceuticals | Pneomococcal Vaccine | Pneumonia | Research | Science | Skin | Skin Biopsy | Sports Medicine | Statistics | Stem Cell Therapy | Stem Cells | Study | Toxicology | Translocation | Transplants | Tuberculosis | Universities & Medical Training | Urology & Nephrology | USA Health | Vaccines | Venture Capital | Veterinary Vaccinations | Vitamins